Article Text

PDF
CP-157 Risk factors associated with thromboembolic disease in hospitalised patients: an assessment in a general specialties hospital
  1. MI Sierra Torres,
  2. CM Valencia Soto,
  3. R Sánchez del Moral,
  4. MD Toscano Guzmán,
  5. E Sánchez Gómez,
  6. C Bocanegra Martín
  1. Complejo Hospitalario Huelva Hospital Juan Ramón Jimenez Y Hospital Infanta Elena, Pharmacy Department, Huelva, Spain

Abstract

Background Thromboembolic disease (TED) is a complex condition in which the interaction between genetic, acquired and environmental factors determines the onset of an episode.

Purpose This study aimed to assess the risk factors (RF) associated with TED in hospitalised patients.

Material and methods A retrospective, descriptive study was conducted in which hospitalised patients with TED from January 2015 to June 2015 were included. Variables included: age, sex, type of TED, previous events, hospitalisation duration, D-dimer elevation, obesity, renal impairment, tabaquism, cardiac and respiratory comorbidities, recent immobilisation or major surgery, family history/genetic predisposition, oncohaematologic history, and treatment with chemotherapy regimens, hormonal therapy, angiogenic agents or erythropoiesis stimulating factors (ESF).

Data were obtained from electronic prescription software (APD-Prisma) and medical records.

Results 108 patients were analysed. There were 6.8 new cases per 1000 admitted patients during the study period. 55% were women. Mean age was 71 years (18–97). 20.3% presented previous TED. Median time of hospitalisation was 8 days (1–91). D-dimer elevation was observed in 63.8% with an average value of 6926.91 (2-48453) (26% absent data).

Of 108 patients, 40.7% presented tabaquism, 22% respiratory complications, 21% cardiac comorbidities, 14.8% obesity and 11% renal impairment. Recent immobilisation or major surgery was noted in 27.8% and 4.6% of cases, respectively. A family history of TED or genetic predisposing mutations were present in 7.4%. Oncohaematologic history was observed in 24%. 8.3% received chemotherapy, 6.5% hormonal therapy and 6.5% ESF. No patient received angiogenic therapy. 28 days mortality was 7.4%.

Conclusion Among our studied population, the incidence of TED was an important issue that grew according to genetic, acquired or environmental factors, consistent with published data. RF evaluation is an essential measure during hospitalisation to minimise these events. Multidisciplinary active programmes for TED prevention should be available.

No conflict of interest

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.